Georgia Medicare Clinical Laboratory Services Benefit

Here is the headline for Georgia Medicare clinical laboratory services: for lab tests billed under the Medicare Clinical Laboratory Fee Schedule (CLFS), you usually pay $0. That means no Part B deductible and no 20 percent coinsurance on the vast majority of routine lab work Georgia seniors get every year, from a cholesterol panel to a diabetes A1c to an INR draw. So if you have Medicare in Georgia and your doctor orders blood work, a biopsy, a Pap smear, or a screening mammogram, this guide explains what Original Medicare pays for and what, in the few cases that carry a cost, you actually owe.

Medicare Part B has covered diagnostic laboratory tests since 1965 under Section 1861(s)(3) of the Social Security Act. This guide walks a Georgia beneficiary through what that means in plain terms: which lab tests are covered and which are not, why a few still carry a coinsurance (anatomic pathology read by a pathologist is paid differently), how the preventive screening tests work and how often you can get them, how Palmetto GBA processes and sometimes denies Georgia lab claims, and exactly what to do when a claim is denied. Four worked examples follow real Georgia scenarios, from annual blood work in Atlanta to homebound monitoring in Athens, and an FAQ closes the rest.

What Georgia Medicare Clinical Laboratory Services Cover, and the Law Behind It

The Medicare clinical laboratory services benefit rests on several layers of law that have accumulated since Medicare began in 1965. The layers matter because coverage disputes are common, particularly for tests not spelled out in a National Coverage Determination and for tests whose coverage depends on a specific diagnosis.

Section 1861(s)(3) of the Social Security Act, codified at 42 U.S.C. 1395x(s)(3), is the foundation that makes diagnostic laboratory tests a Medicare Part B benefit. It covers tests furnished by independent laboratories, hospital outpatient laboratories, and physician office laboratories. Coverage is limited to tests that meet the Section 1862(a)(1)(A) reasonable-and-necessary standard plus any applicable National or Local Coverage Determination.

Section 1833(h) of the Social Security Act, codified at 42 U.S.C. 1395l(h), establishes the Clinical Laboratory Fee Schedule. The CLFS was enacted by the Deficit Reduction Act of 1984, replacing an older reasonable-charge method with a fee schedule, later consolidated to a single national schedule. The CLFS pays for "clinical diagnostic laboratory tests" (CDLTs): chemistry panels, hematology, microbiology, immunology, urinalysis, molecular pathology, and other tests that generally do not require a pathologist's interpretation.

Critically, Section 1833(a)(1)(D)(i) exempts CLFS tests from the Part B deductible and the 20 percent coinsurance. This is one of the most significant cost-sharing exemptions in Part B, reflecting a long-standing policy of encouraging diagnostic and preventive testing. By contrast, services paid under the Medicare Physician Fee Schedule follow standard Part B rules: after you meet the annual deductible ($283 in 2026), you owe 20 percent of the Medicare-approved amount.2

Section 1834A of the Social Security Act, codified at 42 U.S.C. 1395m-1, is the reform added by the Protecting Access to Medicare Act of 2014 (PAMA 2014). It requires "applicable laboratories" to report private payer rate and volume data for each CLFS billing code, and authorizes CMS to set each rate at a weighted median of those private rates.

Section 1861(nn) establishes screening Pap smear and screening pelvic examination as covered preventive services. Screening mammography is covered under 42 CFR 410.34, and colorectal cancer screening under Section 1834(g). These preventive services are discussed in detail below.

Section 1862(a)(1)(A) of the Social Security Act is the reasonable-and-necessary standard. Even a test technically within the CLFS is not paid unless it was reasonable and necessary for the patient's diagnosis or treatment.

Section 1869(f) of the Social Security Act frames National Coverage Determinations (NCDs), issued by CMS and applied nationally, and Local Coverage Determinations (LCDs), issued by Medicare Administrative Contractors and applied only within a jurisdiction.

42 CFR 410.32 requires that diagnostic tests be ordered by the treating physician for diagnosing or treating an illness or injury, the mechanism that prevents standing orders and mass screening unrelated to clinical care.

42 CFR 410.33 establishes the Independent Diagnostic Testing Facility (IDTF) framework, with 14 performance standards. 42 CFR Part 414, Subpart G implements the CLFS payment methodology. 42 CFR Part 493 implements the Clinical Laboratory Improvement Amendments of 1988 (CLIA), the quality and personnel standards for every lab testing human specimens.

The Clinical Laboratory Fee Schedule and PAMA 2014 Market-Based Reform

The Clinical Laboratory Fee Schedule pays for clinical diagnostic laboratory tests (CDLTs): automated chemistry panels, hematology, microbiology, immunology, urinalysis, molecular pathology, and similar tests that generally do not require a pathologist's interpretation. Anatomic pathology (biopsy interpretation, cytology review, immunohistochemistry) is paid under the Medicare Physician Fee Schedule instead, which is why those services carry a coinsurance while CLFS tests do not.

Pre-2018 CLFS methodology

From 1984 through 2017, the CLFS operated as a national fee schedule with annual updates tied to the Consumer Price Index or, in some years, frozen or cut by Congress. The base rates were largely set in 1984 with adjustments over the decades. By the early 2010s, multiple studies found Medicare CLFS rates substantially exceeded what private insurers paid for the same tests.

PAMA 2014 Section 216 reform

The Protecting Access to Medicare Act of 2014 ordered fundamental reform by adding Section 1834A to the Social Security Act, establishing a market-based payment method. The mechanism works like this: applicable laboratories (those meeting defined revenue thresholds) collect private payer rate and volume data for each billing code during a data collection period; they report it to CMS; CMS calculates a weighted median of the private rates; and the weighted median becomes the new CLFS rate. To prevent abrupt disruption, annual payment reductions are capped by statute.

Reporting delays and methodology challenges

The PAMA reform has been delayed repeatedly. The data reporting periods were postponed by successive appropriations acts and continuing resolutions to give CMS and Congress time to revisit the methodology, particularly the definition of "applicable laboratory" (hospital outreach laboratories were largely excluded from the original reporting, raising questions about how representative the data was). None of this changes what a beneficiary pays.

Advanced Diagnostic Laboratory Tests (ADLTs)

Section 1834A created a separate pricing path for Advanced Diagnostic Laboratory Tests, defined as clinical diagnostic tests that are offered and furnished only by a single laboratory, covered under Medicare, and either molecular analyses of multiple biomarkers or otherwise novel tests cleared or approved by the FDA. For an ADLT, the first three quarters are priced at the laboratory's list price, after which the test transitions to market-based rates.

Cost-sharing exemption

PAMA did not change the long-standing CLFS cost-sharing exemption under Section 1833(a)(1)(D)(i). The mechanism sits in the payment rule itself: Medicare pays 80 percent of the fee-schedule amount for most Part B services, but 100 percent for a clinical diagnostic laboratory test when payment is made on an assignment-related basis, so there is no 20 percent coinsurance left for you to owe. A beneficiary usually pays nothing for a Medicare-covered clinical diagnostic laboratory test that a doctor or other health care provider ordered: no Part B deductible, no coinsurance.1

That stands in contrast to the standard Part B rule (the annual deductible plus 20 percent coinsurance) that applies to most other outpatient services, which is why the exemption is the single most important cost rule in the Medicare laboratory benefit.2

CLIA 1988: Federal Quality Standards for All Clinical Laboratories

The Clinical Laboratory Improvement Amendments of 1988 (Public Law 100-578), codified principally at 42 U.S.C. 263a (Section 353 of the Public Health Service Act), set federal quality and personnel standards for all laboratories testing human specimens for health assessment, diagnosis, prevention, or treatment. Implementation is at 42 CFR Part 493.

CLIA applies to virtually every clinical laboratory in the country, from large national reference labs to hospital central labs to physician office labs. A laboratory cannot legally test human specimens for clinical purposes, or bill Medicare for that testing, without an appropriate CLIA certificate.

Three CLIA certificate types

1. Certificate of Waiver: for laboratories performing only "waived" tests, which the FDA categorizes as simple with an insignificant risk of an erroneous result, performed by following the manufacturer's instructions. Common waived tests include fingerstick blood glucose, urine dipstick, rapid strep and rapid flu, the fecal occult blood test, a urine pregnancy test, and selected hemoglobin A1c and INR devices. A Certificate of Waiver is the simplest CLIA certificate, with an annual fee and no personnel standards beyond following instructions, and waived labs face limited oversight.

2. Provider-Performed Microscopy (PPM): for physicians (or PAs, NPs, and CNSs with appropriate credentialing) who personally perform certain direct microscopy tests during a patient encounter, such as wet mounts, KOH preparations, pinworm examinations, and urine sediment examinations. PPM certification requires the practitioner to personally perform the test at the point of care.

3. Certificate of Compliance (CoC) or Certificate of Accreditation (CoA): for laboratories performing moderate-complexity, high-complexity, or PPM tests. CoC labs are surveyed by CMS or the state survey agency. CoA labs are surveyed by CMS-deemed Accreditation Organizations, including:

• College of American Pathologists (CAP): the most common accreditor for hospital and reference labs
• The Joint Commission (TJC)
• COLA: common for physician office labs and small independent labs
• American Association of Blood Banks (AABB): for blood banks and transfusion services
• American Society for Histocompatibility and Immunogenetics (ASHI)

Personnel standards by test complexity

CLIA categorizes tests as waived, moderate-complexity, or high-complexity based on FDA categorization, and personnel standards scale with complexity:

• Moderate-complexity testing: the laboratory director must hold qualified credentials (MD/DO, doctoral-level scientist, or a specified bachelor's-plus-experience path). Testing personnel need at least an associate degree in laboratory science or equivalent training. A technical consultant and clinical consultant are required.
• High-complexity testing: the laboratory director must be a board-certified pathologist or a doctoral-level scientist with specified credentials. A technical supervisor is required for each specialty, along with a clinical consultant, and testing personnel must meet specific education and training standards.

Quality control and proficiency testing

• Quality control requirements vary by specialty and complexity, with daily documentation for most tests.
• Proficiency testing runs three times per year for most regulated analytes: the lab receives samples from an approved provider, tests them as patient samples, and submits results.
• Failing proficiency testing triggers enforcement: a directed plan of correction, suspension of testing in the specialty, or, in extreme cases, certificate revocation.

Survey and enforcement

CLIA inspections occur every two years. Inspectors review records, observe testing, interview personnel, and cite deficiencies by severity: standard-level (corrected through a plan of correction), condition-level (more serious), and immediate jeopardy (a severe risk to patients that can bring suspension or revocation). Enforcement can include civil monetary penalties, certificate suspension or revocation, and, for willful fraud, criminal prosecution.

National Coverage Determinations for Laboratory Tests

Several National Coverage Determinations specifically address laboratory tests, setting covered indications, frequency limits, and diagnosis-code requirements. Among the most important:

• Prostate-Specific Antigen (PSA): covers PSA testing to diagnose prostate cancer and to monitor patients already diagnosed, with specified indications. Separately, screening PSA is covered once every 12 months for men over age 50 at no cost.3
• Thyroid Testing: covers TSH, free T4, free T3, T3 uptake, total T4, and total T3 for specific indications such as suspected hyper- or hypothyroidism and monitoring of thyroid replacement therapy.
• Lipid Testing: covers total cholesterol, HDL, LDL, and triglycerides for evaluating suspected lipid disorders, monitoring established ones, and cardiovascular risk assessment.
• Glycated Hemoglobin (A1c): covers hemoglobin A1c for diabetes diagnosis and monitoring.
• Blood Counts: covers the complete blood count for specific indications.
• Human Immunodeficiency Virus (HIV): covers HIV testing for diagnosis and monitoring.
• Hepatitis Panel: covers hepatitis testing panels for specific indications.
• Tumor Antigens (CA 125, CA 15-3/27-29, CA 19-9): cover tumor markers for specific oncologic indications.

Each NCD lists the covered ICD-10 diagnosis codes that establish medical necessity. Laboratories and ordering providers must include a covered diagnosis code to avoid a denial.

Local Coverage Determinations Issued by Palmetto GBA for Georgia

Palmetto GBA Jurisdiction J issues Local Coverage Determinations that apply in Georgia, Alabama, and Tennessee, covering laboratory tests not addressed by national NCDs. Examples include:

• Molecular pathology procedures
• Drug testing panels
• Allergy testing
• Vitamin D testing
• Tumor genetic tests
• Genetic testing for hereditary cancer syndromes

LCDs spell out covered and non-covered indications, ICD-10 diagnosis-code requirements, and documentation requirements. Providers should consult the current Palmetto GBA LCD database before billing.

Screening Laboratory Tests and Statutory Frequency Limits

Several preventive laboratory and screening tests are covered at no cost when you meet Medicare's age and frequency rules, provided the doctor accepts assignment.4

Screening Pap smear and pelvic exam (Section 1861(nn))

• Covered once every 24 months for women not at high risk for cervical or vaginal cancer.4
• Covered once every 12 months for women at high risk (a clinical history such as DES exposure, an abnormal Pap history, or immunocompromised status).
• HCPCS Q0091 covers obtaining the screening Pap specimen; the Pap test itself is billed separately.
• You pay nothing for the screening.

Screening mammography (42 CFR 410.34)

• A screening mammogram is covered once every 12 months for women age 40 and older, plus one baseline mammogram for a woman ages 35 to 39.5
• HCPCS 77067 covers a bilateral screening mammogram.
• You pay nothing for a screening mammogram when the provider accepts assignment.
• A diagnostic mammogram (after an abnormal screening result or for a woman with symptoms) is not a no-cost preventive service: after you meet the annual Part B deductible ($283 in 2026), you pay 20 percent of the Medicare-approved amount.5

Colorectal cancer screening (Section 1834(g))

Medicare covers several colorectal screening modalities:

• Fecal occult blood test (FOBT) or fecal immunochemical test (FIT): annual, for beneficiaries age 45 and older.
• Multi-target stool DNA test (Cologuard): covered on a set interval for eligible beneficiaries.
• Flexible sigmoidoscopy: covered at defined intervals.
• Screening colonoscopy: covered based on risk level and screening history.

If a polyp or tissue is found and removed during a screening colonoscopy, the visit becomes diagnostic. Under a statutory phase-down, the beneficiary pays 15 percent of the Medicare-approved amount for services in 2026, dropping to 10 percent for 2027 through 2029 and to nothing from 2030 onward, with the Part B deductible waived.4

Other preventive screening tests

• Cardiovascular (lipid) screening: covered on a set interval for at-risk beneficiaries.
• Diabetes screening: covered for at-risk beneficiaries, with more than one test per year possible based on clinical criteria.
• HIV screening: covered annually for at-risk beneficiaries.
• Hepatitis C screening: one-time for at-risk beneficiaries and annually for those at high risk.
• Lung cancer screening: an annual low-dose CT for qualifying beneficiaries ages 50 to 77 with a significant smoking history, paired with the required counseling visit.4

The Independent Diagnostic Testing Facility Framework

The Independent Diagnostic Testing Facility (IDTF) is a separate Medicare provider type established at 42 CFR 410.33. IDTFs are fixed-location, mobile, or individual entities that furnish diagnostic procedures under physician supervision. Common examples include freestanding imaging centers, sleep study laboratories, and electrocardiography laboratories.

The 14 IDTF performance standards (42 CFR 410.33(g))

An IDTF must:

1. Demonstrate operational capability to furnish every service listed on its enrollment application.
2. Comply with applicable federal and state licensure and regulatory requirements.
3. Provide complete and accurate information on its enrollment application.
4. Maintain a physical site at the location on its enrollment application.
5. Maintain a comprehensive liability insurance policy meeting the minimum coverage required by 42 CFR 410.33(g)(5).
6. Maintain medical and patient records.
7. Comply with the HIPAA privacy and security regulations.
8. Operate consistently with applicable state licensure requirements.
9. Be open and operating during posted hours.
10. Have one or more supervising physicians.
11. Permit unannounced site visits by CMS or its agents.
12. Provide written notice of changes in operations or ownership.
13. Maintain complete documentation.
14. Meet other standards as specified in the regulation.

IDTF supervision levels

Diagnostic tests furnished by IDTFs require physician supervision at one of three levels:

• General supervision: the physician must be available by telephone but need not be present.
• Direct supervision: the physician must be in the office suite and immediately available.
• Personal supervision: the physician must be in attendance during the procedure.

Most diagnostic tests require general supervision; certain higher-complexity procedures require direct or personal supervision.

Specimen Collection Fees

Medicare pays separately for specimen collection in defined circumstances:

• HCPCS 36415: routine venipuncture, paid under Part B.
• HCPCS P9612: collection of a capillary blood specimen.
• HCPCS G0471: collection of venous blood by venipuncture in a SNF or home health setting.
• HCPCS P9603 and P9604: travel allowance for collection from a homebound patient or a patient in a SNF.

The travel allowance matters most for mobile phlebotomy serving homebound Georgia beneficiaries. LabCorp and Quest both offer mobile phlebotomy in metro Atlanta, Macon, Savannah, Augusta, and other Georgia cities, and hospital-affiliated home health programs and independent mobile phlebotomy services also reach rural Georgia.

Hospital Outpatient Laboratory: CLFS or OPPS

A common point of confusion is how a hospital outpatient laboratory test is paid. The general rules:

• A hospital outpatient lab test furnished on the same day as other outpatient hospital services: generally bundled into the hospital Outpatient Prospective Payment System (OPPS) payment for the primary service, and not separately payable under the CLFS.
• A hospital outpatient lab test furnished as a standalone service (no other hospital services that day): separately payable under the CLFS.
• A hospital inpatient lab test: bundled into the inpatient (DRG) payment for the admission, and not separately payable.
• Physician office and independent laboratory tests: paid under the CLFS.

These distinctions affect both what the laboratory is paid and what you owe, because CLFS tests are exempt from cost-sharing while OPPS-bundled tests follow OPPS cost-sharing.

Palmetto GBA and Georgia Medicare Clinical Laboratory Services Claims

Palmetto GBA is the Medicare Administrative Contractor for Part B claims in Jurisdiction J, which covers Georgia, Alabama, and Tennessee. Palmetto's responsibilities include:

• Claims processing and payment for clinical laboratory services
• Local Coverage Determinations for tests not addressed by NCDs
• The first level of appeal (redetermination) when a claim is denied
• Coding and billing education for laboratories and ordering providers
• Provider enrollment for Georgia laboratories

Palmetto GBA Jurisdiction J contact information is available at palmettogba.com.

The Georgia Laboratory Landscape

Hospital central laboratories

Each major Georgia hospital system runs a central laboratory plus satellites for its inpatient, outpatient, and physician-practice testing. Major Georgia hospital laboratories include those at Emory Healthcare (Atlanta), Piedmont Healthcare (statewide), Wellstar Health System, Northeast Georgia Health System (Gainesville), Memorial Health (Savannah), Augusta University Health, Atrium Health Navicent (Macon), Phoebe Putney (Albany), and Grady Health System (Atlanta).

National laboratory chains

Two national chains have extensive Georgia operations:

• LabCorp: with hundreds of patient service centers across Georgia and a broad network of in-office partnerships with Georgia physician practices.
• Quest Diagnostics: with hundreds of patient service centers across Georgia and a similar in-office partnership network.

Both run hub-and-spoke logistics with regional core laboratories serving Georgia and nearby states, plus specialized national laboratories for complex molecular and pathology testing.

Specialty and reference laboratories

For complex testing not performed by hospital or chain laboratories, specimens may be sent to:

• Foundation Medicine, Tempus, NeoGenomics, Caris Life Sciences (oncology genomics)
• Mayo Clinic Laboratories, ARUP Laboratories (reference testing)
• Ambry Genetics, GeneDx, Invitae (hereditary cancer and genetic testing)

Physician office laboratories

Many Georgia primary care, urgent care, and specialty practices run small office laboratories under a CLIA Certificate of Waiver or Provider-Performed Microscopy. Common point-of-care tests include fingerstick glucose, urinalysis, rapid strep, rapid flu, and INR.

Georgia DPH Bureau of Laboratories

The Georgia DPH Bureau of Laboratories is the state public health laboratory in Decatur. It performs newborn screening, infectious disease surveillance, environmental testing, and emergency response testing. It is not a clinical service laboratory for individual beneficiaries.

Worked Examples: Georgia Medicare Clinical Laboratory Scenarios

The following examples are illustrative and use hypothetical Georgia beneficiaries.

Example 1: Margaret, 78, Atlanta, annual blood work at Piedmont Atlanta

Margaret attends her annual wellness visit at Piedmont Atlanta. Her physician orders a complete blood count (CBC, HCPCS 85025) and a comprehensive metabolic panel (CMP, HCPCS 80053). The phlebotomist draws the specimen and the tests run on Piedmont's automated analyzers.

Billing:

• HCPCS 85025 CBC: paid under CLFS
• HCPCS 80053 CMP: paid under CLFS
• HCPCS 36415 venipuncture: paid under Part B

Margaret's cost: nothing on the lab tests, thanks to the CLFS cost-sharing exemption. She owes the standard Part B coinsurance on the venipuncture and the physician visit, which her Medigap Plan G covers.

Example 2: Robert, 82, Savannah, annual PSA screening at Memorial Health

Robert receives an annual PSA screening as part of preventive care. His physician orders a total PSA (HCPCS 84153) as a screening test, drawn at Memorial Health's outpatient laboratory.

Billing:

• HCPCS 84153 PSA screening: paid under CLFS as a preventive screening
• No cost-sharing under the preventive services rules

If the PSA is elevated and Robert's urologist orders a reflex free PSA (HCPCS 84154), that test is diagnostic rather than screening but is still on the CLFS, so Robert still owes nothing.

Example 3: Charles, 80, Augusta, colorectal cancer with tumor markers and genomics at AU Medical Center

Charles is diagnosed with stage III colon adenocarcinoma after a colonoscopy and biopsy. The oncology team orders several tests:

• Tumor markers: CEA (HCPCS 82378) and CA 19-9 (HCPCS 86301). Paid under CLFS, no cost-sharing.
• Molecular pathology: KRAS, NRAS, and BRAF mutation testing. Paid under CLFS or the Physician Fee Schedule depending on whether interpretation is required.
• Mismatch repair (MMR) immunohistochemistry: HCPCS 88341 per marker. Paid under the Physician Fee Schedule as a pathology professional service.
• Comprehensive genomic profiling: if the oncologist orders an FDA-approved companion diagnostic, the test may qualify as an Advanced Diagnostic Laboratory Test.

Charles's cost: nothing on the CLFS tests, and the standard 20 percent coinsurance after the annual Part B deductible ($283 in 2026) on the Physician Fee Schedule pathology services, covered by his Medigap.2

Example 4: Henry, 85, Athens, dual-eligible QMB, homebound monthly INR monitoring

Henry is bedbound at home in Athens with atrial fibrillation requiring warfarin and monthly INR monitoring. His physician orders a monthly INR (HCPCS 85610), and LabCorp mobile phlebotomy serves his home.

Billing:

• HCPCS 85610 prothrombin time/INR: paid under CLFS, no cost-sharing
• HCPCS G0471 collection of venous blood in the home: paid under Part B
• HCPCS P9604 travel allowance per visit

Henry is a Qualified Medicare Beneficiary (QMB), one of the Medicare Savings Programs, enrolled in Georgia Medicaid, which covers any Medicare cost-sharing under Section 1902(n)(3)(B). LabCorp must accept the Medicare-allowed amount as payment in full and cannot balance-bill Henry.

Common Mistakes Georgia Medicare Laboratory Beneficiaries Should Avoid

1. Assuming a non-CLIA-certified laboratory can bill Medicare. Every laboratory testing Medicare specimens must have an appropriate CLIA certificate. Confirm it before service.

2. Missing the diagnosis-code requirement. Laboratory claims must carry ICD-10 diagnosis codes that establish medical necessity under the applicable NCD or LCD.

3. Confusing screening with diagnostic testing. Screening tests have specific frequency limits and can carry different cost-sharing.

4. Not understanding the CLFS cost-sharing exemption. There is normally no Part B deductible and no coinsurance for clinical laboratory tests paid under the CLFS, so a bill for one is worth questioning.

5. Confusing CLFS with the Physician Fee Schedule. Anatomic pathology (biopsy interpretation, special stains, immunohistochemistry) is paid under the Physician Fee Schedule and carries a coinsurance.

6. Not appealing a denied lab claim through Palmetto GBA. The first level of appeal (redetermination) is available for any denial.

7. Failing to get an Advance Beneficiary Notice (ABN) when the lab expects a denial. Without an ABN, the laboratory cannot bill you for a denied service.

8. Confusing a CLIA Certificate of Waiver with full CLIA certification. Waived-certificate labs may perform only FDA-categorized waived tests.

9. Missing the COVID-19 testing rules after the public health emergency. The no-cost rule for diagnostic COVID-19 testing applied during the PHE; afterward, standard Part B rules apply to tests not paired with a covered medical visit.

Where to Get Help in Georgia

Learn More

Find personalized help navigating Georgia Medicare clinical laboratory benefits at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.